While it has been hypothesized that complement inhibition may form a viable target for the treatment of NASH, we did not find any effect of anti-C5 treatment on liver steatosis and inflammation despite a significant inhibition of MAC deposition in the liver. This evidence concerns the gene C5 and fatty liver disease.